AU2021409196A1 - Method for producing naive human ips cells from somatic cells - Google Patents

Method for producing naive human ips cells from somatic cells Download PDF

Info

Publication number
AU2021409196A1
AU2021409196A1 AU2021409196A AU2021409196A AU2021409196A1 AU 2021409196 A1 AU2021409196 A1 AU 2021409196A1 AU 2021409196 A AU2021409196 A AU 2021409196A AU 2021409196 A AU2021409196 A AU 2021409196A AU 2021409196 A1 AU2021409196 A1 AU 2021409196A1
Authority
AU
Australia
Prior art keywords
gene
vectors
cells
protein
naive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021409196A
Other languages
English (en)
Other versions
AU2021409196A9 (en
Inventor
Jitsutaro KAWAGUCHI
Akira KUNITOMI
Tsugumine Shu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Pharma Co Ltd
Kyoto University NUC
Original Assignee
ID Pharma Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Pharma Co Ltd, Kyoto University NUC filed Critical ID Pharma Co Ltd
Publication of AU2021409196A1 publication Critical patent/AU2021409196A1/en
Publication of AU2021409196A9 publication Critical patent/AU2021409196A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021409196A 2020-12-25 2021-12-24 Method for producing naive human ips cells from somatic cells Pending AU2021409196A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020217472 2020-12-25
JP2020-217472 2020-12-25
PCT/JP2021/048397 WO2022138964A1 (ja) 2020-12-25 2021-12-24 体細胞からのナイーブ型ヒトｉＰＳ細胞製造方法

Publications (2)

Publication Number Publication Date
AU2021409196A1 true AU2021409196A1 (en) 2023-08-03
AU2021409196A9 AU2021409196A9 (en) 2024-05-16

Family

ID=82158245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021409196A Pending AU2021409196A1 (en) 2020-12-25 2021-12-24 Method for producing naive human ips cells from somatic cells

Country Status (9)

Country Link
US (1) US20240060051A1 (https=)
EP (1) EP4269571A4 (https=)
JP (1) JPWO2022138964A1 (https=)
KR (1) KR20230126717A (https=)
CN (1) CN116802275A (https=)
AU (1) AU2021409196A1 (https=)
CA (1) CA3203232A1 (https=)
IL (1) IL303975A (https=)
WO (1) WO2022138964A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116004512A (zh) * 2022-12-30 2023-04-25 深圳市康宁医院 一种利用外泌体制备诱导性多能干细胞的方法及其试剂和应用
AU2024232721A1 (en) * 2023-03-03 2025-10-09 Kyoto University Method for producing primed pluripotent stem cells
WO2025151477A1 (en) * 2024-01-09 2025-07-17 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of producing rejuvenated human somatic cells, compositions, and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
DK0864645T3 (da) 1995-10-31 2005-10-24 Dnavec Research Inc Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US6130313A (en) 1997-10-02 2000-10-10 Clontech Laboratories, Inc. Rapidly degrading GFP-fusion proteins
KR100739938B1 (ko) 1999-05-18 2007-07-16 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
EP1211318B1 (en) 1999-09-06 2007-08-08 DNAVEC Research, Inc. Paramyxoviruses comprising a modified transcription start sequence
JPWO2003025570A1 (ja) 2001-09-18 2004-12-24 株式会社ディナベック研究所 粒子形成能が低下した（−）鎖ｒｎａウィルスベクターの検査方法および製造方法
JP4528623B2 (ja) 2002-09-16 2010-08-18 プロメガ コーポレイション 迅速分解性レポーター融合タンパク質
JP4999330B2 (ja) 2004-01-22 2012-08-15 株式会社ディナベック研究所 サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法
JP4901471B2 (ja) 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
WO2006137517A1 (ja) 2005-06-24 2006-12-28 Dnavec Corporation 幼少個体への遺伝子導入用ベクター
JP4944781B2 (ja) 2005-09-15 2012-06-06 独立行政法人科学技術振興機構 テトラサイクリン系抗生物質によるタンパク質分解制御法
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
CA2636600A1 (en) 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
KR20090052857A (ko) 2006-07-13 2009-05-26 디나벡크 가부시키가이샤 비복제형 파라믹소바이러스과 바이러스 벡터
US8173792B2 (en) 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
JP5278942B2 (ja) 2007-12-03 2013-09-04 独立行政法人産業技術総合研究所 タンパク質短寿命化ペプチドをコードする遺伝子及びその使用方法
US9127256B2 (en) 2008-07-16 2015-09-08 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
JP5605658B2 (ja) 2009-04-30 2014-10-15 国立大学法人大阪大学 哺乳類細胞におけるタンパク質分解誘導方法
EP2434012B1 (en) * 2009-05-18 2017-12-13 National Institute of Advanced Industrial Science And Technology Vector material for creating pluripotent stem cells, and pluripotent stem cell creation method using said vector material
US8496941B2 (en) * 2009-06-03 2013-07-30 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
JP2011101639A (ja) 2009-10-16 2011-05-26 Kumamoto Univ タンパク質低発現化ペプチドをコードする遺伝子およびその使用方法
EP2537930A4 (en) * 2010-02-18 2013-10-02 Univ Osaka METHOD FOR THE PRODUCTION OF INDUCED PLURIPOTENTAL STEM CELLS
CA2809515A1 (en) * 2010-08-30 2012-03-08 Dnavec Corporation Composition for inducing pluripotent stem cell, and use thereof
US10975358B2 (en) * 2013-09-24 2021-04-13 Id Pharma Co., Ltd. Method for improving efficiency of inducing pluripotent stem cell
JP6366944B2 (ja) 2014-01-24 2018-08-01 国立大学法人 東京大学 プライム型多能性幹細胞からキメラ形成能を向上させた多能性幹細胞を製造する方法並びにそのための組成物および組合せ
EP3183336B2 (en) * 2014-08-22 2025-07-09 Cambridge Enterprise Limited Resetting pluripotent stem cells
JP6769880B2 (ja) * 2015-02-02 2020-10-14 株式会社Ｉｄファーマ 改良されたマイナス鎖ｒｎａウイルスベクター
US10738280B2 (en) 2015-03-18 2020-08-11 Ono Pharmaceutical Co., Ltd. Method for producing naïve pluripotent stem cells
US20180142206A1 (en) 2015-05-05 2018-05-24 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Reversion of primed pluripotent stem cells to naive pluripotent stem cells
WO2017082174A1 (ja) 2015-11-13 2017-05-18 株式会社Ｉｄファーマ 改良されたパラミクソウイルスベクター
EP3438248A4 (en) 2016-03-30 2019-11-06 Kyowa Hakko Bio Co., Ltd. NAIVES PLURIPOTENT STEM CELL CULTIVATION MEDIUM AND PLURIPOTENT STEM CELL CULTIVATION PROCEDURE
WO2019093340A1 (ja) * 2017-11-07 2019-05-16 国立大学法人京都大学 ナイーブ型多能性幹細胞からの原始内胚葉誘導方法
CN111684063A (zh) * 2018-01-31 2020-09-18 富士胶片株式会社 细胞的制造方法
WO2020153478A1 (ja) * 2019-01-25 2020-07-30 国立研究開発法人産業技術総合研究所 人工マイクロｒｎａ前駆体およびそれを含む改良されたマイクロｒｎａ発現ベクター
JP7762490B2 (ja) * 2019-05-31 2025-10-30 チルドレンズ ホスピタル メディカル センター 細胞リプログラミングのための組成物および方法
US11981932B2 (en) * 2020-06-17 2024-05-14 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells

Also Published As

Publication number Publication date
AU2021409196A9 (en) 2024-05-16
CN116802275A (zh) 2023-09-22
EP4269571A4 (en) 2025-01-01
KR20230126717A (ko) 2023-08-30
EP4269571A1 (en) 2023-11-01
JPWO2022138964A1 (https=) 2022-06-30
WO2022138964A1 (ja) 2022-06-30
IL303975A (en) 2023-08-01
US20240060051A1 (en) 2024-02-22
CA3203232A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CN102159710B (zh) 使用染色体非整合型病毒载体制造经初始化的细胞的方法
AU2011297075B2 (en) Composition for inducing pluripotent stem cell, and use thereof
US20240060051A1 (en) Method for Producing Naive Human IPS Cells From Somatic Cells
CN105916980B (zh) 用于改进诱导多能干细胞的效率的方法
HK40099220A (zh) 从体细胞制备幼稚型人ips细胞的方法
JP5763340B6 (ja) 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法

Legal Events

Date Code Title Description
SREP Specification republished